Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4399438 | 0.93 | DHODH (0.74) | DHODHDHFR | |
| SCHEMBL517489 | 0.84 | DHODH (1.00) | DHODHDHFR | |
| SCHEMBL299933 | 0.81 | DHODH (1.00) | DHODHDHFR | |
| SCHEMBL20673116 | 0.81 | DHODH (0.64) | DHODHDHFR | |
| SCHEMBL25839308 | 0.77 | DHODH (0.83) | DHODHDHFR | |
| SCHEMBL31326983 | 0.77 | DHODH (0.83) | DHODHDHFR | |
| SCHEMBL14452168 | 0.77 | DHODH (0.85) | DHODH | |
| SCHEMBL31026697 | 0.76 | DHODH (0.77) | DHODHDHFR | |
| SCHEMBL25839326 | 0.76 | DHODH (0.80) | DHODHDHFR | |
| SCHEMBL25839318 | 0.76 | DHODH (0.77) | DHODHDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015154820-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | PANOPTES PHARMA GMBH (AT) | 2015-10-15 | — | — | WO | claimed |
| US-8354433-B2 | Anti-inflammatory agents as virostatic compounds | 4SC AG (DE) | 2013-01-15 | — | — | US | claimed |
| US-20230285355-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | KIORA PHARMACEUTICALS GMBH (AT) | 2023-09-14 | — | — | US | disclosed |
| US-11730716-B2 | Compounds for treating ophthalmic diseases and disorders | KIORA PHARMACEUTICALS GMBH (AT) | 2023-08-22 | — | — | US | disclosed |
| EP-3328843-B1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2022-10-26 | — | — | EP | disclosed |
| EP-2427186-B1 | DIHYDROOROTATE-DEHYDROGENASEE INHIBITORS AS VIROSTATIC COMPOUNDS | PANOPTES PHARMA GES M B H (AT) | 2022-01-12 | — | — | EP | disclosed |
| US-20210088520-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | SERVIER PHARMACEUTICALS LLC | 2021-03-25 | — | — | US | disclosed |
| US-20180251437-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-09-06 | — | — | US | disclosed |
| EP-3328843-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2018-06-06 | — | — | EP | disclosed |
| US-9795590-B2 | Anti-inflammatory agents as virostatic compounds | PANOPTES PHARMA GMBH (AT) | 2017-10-24 | — | — | US | disclosed |
| US-9795590-B2 | Anti-inflammatory agents as virostatic compounds | PANOPTES PHARMA GMBH (AT) | 2017-10-24 | — | — | US | disclosed |
| WO-2010052027-A1 | COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2010-05-14 | — | — | WO | disclosed |
| EP-1581477-B1 | CYCLOALKENE DICARBOXYLIC ACID COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2009-12-02 | — | — | EP | disclosed |
| US-20070224672-A1 | Method of Identifying Inhibitors of DHODH | LEBAN JOHANN | 2007-09-27 | — | — | US | disclosed |
| US-7247736-B2 | Method of identifying inhibitors of DHODH | 4SC AG (DE) | 2007-07-24 | — | — | US | disclosed |
| US-20070027193-A1 | Method of identifying inhibitors of DHODH | 4SC AG (DE) | 2007-02-01 | — | — | US | disclosed |
| US-7071355-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4 SC AG (DE) | 2006-07-04 | — | — | US | disclosed |
| EP-1581478-A1 | DHODH-INHIBITORS AND METHOD FOR THEIR IDENTIFICATION | 4SC AG (DE) | 2005-10-05 | — | — | EP | disclosed |
| US-20040176458-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4 SC AG (DE) | 2004-09-09 | — | — | US | disclosed |
| WO-2004056747-A1 | DHODH-INHIBITORS AND METHOD FOR THEIR IDENTIFICATION | 4SC AG (DE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027193-A1 | Method of identifying inhibitors of DHODH | DHODH, SQOR, NDUFA5 | DHODH 1/4885DHFR 67/4885 |
| US-20180251437-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC6, HDAC2 | DHODH 1897/4885DHFR 1521/4885 |
| US-20040176458-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | MSR1, PPARG, PPARA | DHODH 2089/4885DHFR 1198/4885 |
| US-11730716-B2 | Compounds for treating ophthalmic diseases and disorders | DHODH, ALDH1A2, QDPR | DHODH 1/4885DHFR 38/4885 |
| US-20210088520-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | DHODH, IDH1, IDH3A | DHODH 1/4885DHFR 9/4885 |
| US-20230285355-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | DHODH, ALDH1A2, QDPR | DHODH 1/4885DHFR 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.